ReviewThe oncologist2022
Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
Lori J Wirth et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
25 papers cite it
this paperpooled ittrialcites it